# Selank Research: Mechanism, GABA, Enkephalinase & Key Studies > Selank research: positive allosteric GABA modulation, enkephalinase inhibition (IC50 ~15 µM), hippocampal BDNF, GABA-pathway gene shifts, and the Russian clinical record — cited. Each major finding gets its own heading, each quantitative claim its own citation. ## The short version Selank research points to two main ways the peptide may calm anxiety, neither of which works like a benzodiazepine. First, it gently tunes the brain's main "slow down" signaling system — the GABA system — acting as a helper that boosts the receptor's response rather than flooding it. Second, it blocks an enzyme that breaks down the body's own natural calming peptides (enkephalins), so those last a little longer. On top of that, in rats it raised a growth factor called BDNF that supports brain-cell health, and it shifted serotonin and dopamine activity. Most of this comes from animal work and a small set of Russian human studies. The findings below are grouped by mechanism, each tied to a specific paper. The honest limit, stated plainly: this is a concentrated, single-region evidence base, and it does not prove Selank treats any anxiety disorder. ## GABAergic modulation: a non-benzodiazepine mechanism The anchor of the Selank mechanism literature is GABAergic modulation. A 2018 review establishes that Selank's anxiolytic activity centers on its action as a positive allosteric modulator of GABA receptor binding — subtype-selective and concentration-dependent — and reports that it can block the modulatory activity of diazepam and olanzapine, indicating distinct but overlapping binding sites [1]. This is reinforced at the level of gene expression. Selank administration (300 µg/kg in rats) changed the expression of genes involved in GABAergic neurotransmission in the frontal cortex: 45 genes shifted one hour after administration and 22 at three hours, and the direction of those shifts correlated positively with changes produced by GABA itself [4]. Functionally, in an unpredictable chronic mild stress model, the combination of diazepam with Selank was the most effective intervention for reducing anxiety, restoring behavior toward pre-stress levels — consistent with a GABAergic interaction [7]. ## Enkephalinase inhibition and the opioid axis A second, independent mechanism is enzymatic. Selank dose-dependently inhibited the hydrolysis of plasma enkephalins in human plasma in vitro, with an IC50 of approximately 15 µM [2]. By slowing the breakdown of enkephalins — the body's endogenous opioid, anti-stress peptides — Selank is proposed to normalize the shortened enkephalin half-life observed in generalized anxiety. This enkephalinase-inhibition account is one of the more concrete in vitro results in the Selank record and is part of why the peptide is treated as mechanistically distinct from GABA-only sedatives. ## BDNF, neuroplasticity, and memory models Selank's nootropic reputation rests partly on neurotrophic signaling. Intranasal Selank regulated (increased) BDNF expression in the rat hippocampus in vivo, linking the peptide to neuroplasticity [3]. In neurotoxin-lesion models it showed a compensatory effect on memory (mnestic) functions disturbed by the neurotoxin MPTP in rats [13], and a protective effect in a related model of mnestic-function impairment [14]. These are animal findings in injury models, not demonstrations of cognitive enhancement in healthy humans, and they are reported here as such. ## Monoaminergic and serotonergic effects Consistent with this site's monoamine-focused reading of the record, Selank alters monoamine turnover. It was used to correct measures of integrative brain activity and biogenic amine levels in rats [8], and it changed the content of monoamines and their metabolites in the brains of BALB/c and C57Bl/6 mice in a strain-dependent manner [9]. Selank and tuftsin produced comparable effects on serotonin metabolism in rat brain, consistent with Selank being a stabilized tuftsin analog [10]. In a 6-OHDA Parkinsonian model, Selank and Semax both modified dopaminergic-related behavior, with distinct profiles [11] — a useful pointer to the comparison covered on [Selank vs Semax](/vs-semax). ## Immunomodulation: the tuftsin inheritance Because Selank descends from tuftsin, an immunomodulatory peptide, its activity is not confined to the CNS. In patients with anxiety-asthenic disorders, Selank altered the Th1/Th2 cytokine balance and modulated IL-6 expression, characterizing it as an immunomodulator alongside its anxiolytic action [5]. It influenced cytokine levels under stress in rats [18] and showed antiviral activity in experimental influenza infection in mice [19]. This immune axis is a genuine part of the Selank profile — and, as noted on [Selank effects](/effects), a distinct and largely unstudied source of interaction unknowns in people. ## Selank peptide: structure and stability The Selank peptide is the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro (C33H57N11O9; MW 751.9 Da; CAS 129954-34-3). Its design is tuftsin (Thr-Lys-Pro-Arg) extended at the C-terminus with Pro-Gly-Pro, an extension that dramatically slows enzymatic degradation relative to native tuftsin [2]. That stability is the whole point: native tuftsin is too short-lived to be useful, and the proline-rich tail is what gives the molecule a workable functional window. Physiological reach extends even to the gut — the synthetic anxiolytic affected gastric wall blood flow and mucosal protection in rats [15]. ## N-Acetyl Selank N-Acetyl Selank refers to an acetylated variant in which an acetyl group is added at the peptide's N-terminus, a modification commonly used in peptide chemistry to further improve metabolic stability. The mechanistic and clinical literature summarized on this site characterizes Selank itself (Thr-Lys-Pro-Arg-Pro-Gly-Pro) [1][2], and the controlled findings here should be read as describing Selank rather than the N-acetylated form specifically. No separate body of rigorous human N-Acetyl Selank trials is established in mainstream literature, so claims about it should be made cautiously and not treated as interchangeable with the cited Selank record. ## The honest gap Stated without flinching: the great majority of Selank studies come from a small set of Russian research groups, many in Russian-language journals with English abstracts only, and independent Western replication is limited [6]. Pharmacokinetics of intact Selank in humans are poorly characterized in mainstream sources, and most efficacy data are preclinical or from small clinical studies [6]. These limits do not erase the findings above — they frame them. A careful reader should weight the cited mechanisms as genuine and the breadth of the human evidence as preliminary. --- A verification-minded reading of the Selank record — the GABA, enkephalinase and monoamine findings logged to source and tagged by evidence strength, the single-region Russian base and unknown human pharmacokinetics named without flinching; no clinic behind the console, and nothing here dispensed or sold.